Sofinnova closes €725M fund for late-stage life sciences companies

Sofinnova Partners has closed its second crossover fund, Crossover II, at €725 million (about $815 million), exceeding its original target.

The fund will primarily invest in European clinical-stage biopharma and medtech companies approaching commercialization, with selective investments in the U.S. and other markets.

Sofinnova expects to back roughly 15 companies. Its initial investments include Hemab Therapeutics, CellCentric and Neurent Medical.

The fund aims to address a financing gap for companies seeking capital to advance through late-stage development and toward bringing products to market.

Sources:

Sofinnova Partners closes €725M Crossover II Fund

Sofinnova closes €725 million fund to back European biotech expansion

One of Europe's leading VCs banks a €725M 'crossover' fund

Sofinnova books $815M fund toward up-and-coming 'global leaders'

Sofinnova Partners raises €725M fund to back late-stage biotechs

Sofinnova closes €725M fund to back Europe's late-stage ...

EU's life sciences sector gets an $815m injection from Sofinnova

Sofinnova amasses €725M for late-stage European biotechs

Sofinnova seals €725M fund to fuel Europe's late-stage biotechs

Sofinnova Partners backs European life sciences sector with €725M …

Veteran investor closes €725m biotech fund – seeks clinical-stage firms | Impact Loop VC

Sofinnova Raises €725M Fund to Boost European Biotech Expansion

Sofinnova Closes €725 Million Fund to Back European ...

November 2026 - European Biotechnology Magazine

Sofinnova closes €725 million fund to back European ...